Review



mouse anti human bcl2 mab  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Bio-Rad mouse anti human bcl2 mab
    Fig. 6. Hybridoma characterization. (A) Binding constants (nanomolar) of mAbs generated with splenocytes from non-transgenic littermates (LM) and transgenic line 70818 animals <t>(Bcl2)</t> as determined by Biacore analysis (log scale nanomolar). (B) Western blot analysis of Bcl-2 expression in hybridomas from bcl-2 transgenic animals (each line represents one hybridoma). The positive control corresponds to a lysate from human Jurkat cells. The ratio of Bcl-2/GAPDH for each hybridoma is depicted under the respective lines. (C) Concentration of rat IgG in tissue culture supernatants at day 3 of culture (cells between 3.1 and 6 3 105 ml–1) measured by ELISA. Each point represents the values of one hybridoma supernatant and the horizontal bar the mean of each group of values *P < 0.05 hybridoma Bcl-2- (n = 4) versus hybridoma Bcl-2+
    Mouse Anti Human Bcl2 Mab, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human bcl2 mab/product/Bio-Rad
    Average 93 stars, based on 23 article reviews
    mouse anti human bcl2 mab - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Effects of BCL-2 over-expression on B cells in transgenic rats and rat hybridomas."

    Article Title: Effects of BCL-2 over-expression on B cells in transgenic rats and rat hybridomas.

    Journal: International immunology

    doi: 10.1093/intimm/dxr071

    Fig. 6. Hybridoma characterization. (A) Binding constants (nanomolar) of mAbs generated with splenocytes from non-transgenic littermates (LM) and transgenic line 70818 animals (Bcl2) as determined by Biacore analysis (log scale nanomolar). (B) Western blot analysis of Bcl-2 expression in hybridomas from bcl-2 transgenic animals (each line represents one hybridoma). The positive control corresponds to a lysate from human Jurkat cells. The ratio of Bcl-2/GAPDH for each hybridoma is depicted under the respective lines. (C) Concentration of rat IgG in tissue culture supernatants at day 3 of culture (cells between 3.1 and 6 3 105 ml–1) measured by ELISA. Each point represents the values of one hybridoma supernatant and the horizontal bar the mean of each group of values *P < 0.05 hybridoma Bcl-2- (n = 4) versus hybridoma Bcl-2+
    Figure Legend Snippet: Fig. 6. Hybridoma characterization. (A) Binding constants (nanomolar) of mAbs generated with splenocytes from non-transgenic littermates (LM) and transgenic line 70818 animals (Bcl2) as determined by Biacore analysis (log scale nanomolar). (B) Western blot analysis of Bcl-2 expression in hybridomas from bcl-2 transgenic animals (each line represents one hybridoma). The positive control corresponds to a lysate from human Jurkat cells. The ratio of Bcl-2/GAPDH for each hybridoma is depicted under the respective lines. (C) Concentration of rat IgG in tissue culture supernatants at day 3 of culture (cells between 3.1 and 6 3 105 ml–1) measured by ELISA. Each point represents the values of one hybridoma supernatant and the horizontal bar the mean of each group of values *P < 0.05 hybridoma Bcl-2- (n = 4) versus hybridoma Bcl-2+

    Techniques Used: Binding Assay, Generated, Transgenic Assay, Western Blot, Expressing, Positive Control, Concentration Assay, Enzyme-linked Immunosorbent Assay



    Similar Products

    98
    Cell Signaling Technology Inc mouse anti human b cell lymphoma 2 bcl2
    IVL DCM induces the apoptosis of A549 cells. A549 cells were treated with the indicated concentrations of IVL DCM for 48 h. ( A ) P53, <t>BCL2,</t> BAX, Caspase 3, c-Caspase 3, PARP, c-PARP protein levels as detected by immunoblotting of A549 cell lysates. β-actin was immunoblotted as a loading control ( B ). Quantification of the bands in ( A ). Bar graphs of band intensity of target proteins normalized to the intensity of the loading control β-actin expressed as fold change of the vehicle control and represented as the mean ± SEM of three independent experiments ( n = 3). The right panel of ( B ) shows the ratio of BAX/BCL2 ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.
    Mouse Anti Human B Cell Lymphoma 2 Bcl2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human b cell lymphoma 2 bcl2/product/Cell Signaling Technology Inc
    Average 98 stars, based on 1 article reviews
    mouse anti human b cell lymphoma 2 bcl2 - by Bioz Stars, 2026-03
    98/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc anti human bcl2 pe
    IVL DCM induces the apoptosis of A549 cells. A549 cells were treated with the indicated concentrations of IVL DCM for 48 h. ( A ) P53, <t>BCL2,</t> BAX, Caspase 3, c-Caspase 3, PARP, c-PARP protein levels as detected by immunoblotting of A549 cell lysates. β-actin was immunoblotted as a loading control ( B ). Quantification of the bands in ( A ). Bar graphs of band intensity of target proteins normalized to the intensity of the loading control β-actin expressed as fold change of the vehicle control and represented as the mean ± SEM of three independent experiments ( n = 3). The right panel of ( B ) shows the ratio of BAX/BCL2 ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.
    Anti Human Bcl2 Pe, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human bcl2 pe/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    anti human bcl2 pe - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc anti human bcl2 af647
    IVL DCM induces the apoptosis of A549 cells. A549 cells were treated with the indicated concentrations of IVL DCM for 48 h. ( A ) P53, <t>BCL2,</t> BAX, Caspase 3, c-Caspase 3, PARP, c-PARP protein levels as detected by immunoblotting of A549 cell lysates. β-actin was immunoblotted as a loading control ( B ). Quantification of the bands in ( A ). Bar graphs of band intensity of target proteins normalized to the intensity of the loading control β-actin expressed as fold change of the vehicle control and represented as the mean ± SEM of three independent experiments ( n = 3). The right panel of ( B ) shows the ratio of BAX/BCL2 ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.
    Anti Human Bcl2 Af647, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human bcl2 af647/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    anti human bcl2 af647 - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    98
    Cell Signaling Technology Inc mouse anti human bcl2
    Fig. 7 | Single-cell transcriptomic analysis verifies lower CELSR2 and higher <t>BCL2</t> in glucocorticoid-resistant primary ALL cells. a, Clustering of single cells (n = 2 patients) based on the top 1,000 most highly expressed genes. Both patients are independent of the discovery and validation cohorts; leukemia cells from one patient are sensitive (left) and from another are resistant to prednisolone (right). Clusters annotated to show CD19+ cells; red denotes control (untreated) and blue depicts cells after treatment with prednisolone 63 µM for 96 h. b, CELSR2 expression from clustered single-cell populations of sensitive and resistant patients either without treatment or after 96 h of prednisolone. c, BCL2 expression from clustered single-cell populations of sensitive and resistant patients. d, Bar plot depicting greater proportion of sensitive leukemia cells (n = 2,427 control cells; n = 924 treated cells) killed after treatment with prednisolone for 96 h compared with resistant patient (n = 686 control cells; n = 759 treated cells; two-proportion z-test P: ****P < 0.0001). e,f, Violin plots representing kernel density of gene expression (individual points represent single cells) of CELSR2 (e) or BCL2 (f) in CD19+ leukemia cell populations comparing prednisolone treated with untreated cells in sensitive (n = 2,427 control cells; n = 924 treated cells) or resistant patients (n = 686 control cells; n = 759 treated cells; **P < 0.01).
    Mouse Anti Human Bcl2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human bcl2/product/Cell Signaling Technology Inc
    Average 98 stars, based on 1 article reviews
    mouse anti human bcl2 - by Bioz Stars, 2026-03
    98/100 stars
      Buy from Supplier

    86
    Thermo Fisher b cell lymphoma 2 protein bcl 2 bcl2 mouse anti human mab
    Fig. 7 | Single-cell transcriptomic analysis verifies lower CELSR2 and higher <t>BCL2</t> in glucocorticoid-resistant primary ALL cells. a, Clustering of single cells (n = 2 patients) based on the top 1,000 most highly expressed genes. Both patients are independent of the discovery and validation cohorts; leukemia cells from one patient are sensitive (left) and from another are resistant to prednisolone (right). Clusters annotated to show CD19+ cells; red denotes control (untreated) and blue depicts cells after treatment with prednisolone 63 µM for 96 h. b, CELSR2 expression from clustered single-cell populations of sensitive and resistant patients either without treatment or after 96 h of prednisolone. c, BCL2 expression from clustered single-cell populations of sensitive and resistant patients. d, Bar plot depicting greater proportion of sensitive leukemia cells (n = 2,427 control cells; n = 924 treated cells) killed after treatment with prednisolone for 96 h compared with resistant patient (n = 686 control cells; n = 759 treated cells; two-proportion z-test P: ****P < 0.0001). e,f, Violin plots representing kernel density of gene expression (individual points represent single cells) of CELSR2 (e) or BCL2 (f) in CD19+ leukemia cell populations comparing prednisolone treated with untreated cells in sensitive (n = 2,427 control cells; n = 924 treated cells) or resistant patients (n = 686 control cells; n = 759 treated cells; **P < 0.01).
    B Cell Lymphoma 2 Protein Bcl 2 Bcl2 Mouse Anti Human Mab, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b cell lymphoma 2 protein bcl 2 bcl2 mouse anti human mab/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    b cell lymphoma 2 protein bcl 2 bcl2 mouse anti human mab - by Bioz Stars, 2026-03
    86/100 stars
      Buy from Supplier

    93
    Bio-Rad mouse anti human bcl2 mab
    Fig. 6. Hybridoma characterization. (A) Binding constants (nanomolar) of mAbs generated with splenocytes from non-transgenic littermates (LM) and transgenic line 70818 animals <t>(Bcl2)</t> as determined by Biacore analysis (log scale nanomolar). (B) Western blot analysis of Bcl-2 expression in hybridomas from bcl-2 transgenic animals (each line represents one hybridoma). The positive control corresponds to a lysate from human Jurkat cells. The ratio of Bcl-2/GAPDH for each hybridoma is depicted under the respective lines. (C) Concentration of rat IgG in tissue culture supernatants at day 3 of culture (cells between 3.1 and 6 3 105 ml–1) measured by ELISA. Each point represents the values of one hybridoma supernatant and the horizontal bar the mean of each group of values *P < 0.05 hybridoma Bcl-2- (n = 4) versus hybridoma Bcl-2+
    Mouse Anti Human Bcl2 Mab, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human bcl2 mab/product/Bio-Rad
    Average 93 stars, based on 1 article reviews
    mouse anti human bcl2 mab - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology mouse anti-human bcl2 mab
    Fig. 6. Hybridoma characterization. (A) Binding constants (nanomolar) of mAbs generated with splenocytes from non-transgenic littermates (LM) and transgenic line 70818 animals <t>(Bcl2)</t> as determined by Biacore analysis (log scale nanomolar). (B) Western blot analysis of Bcl-2 expression in hybridomas from bcl-2 transgenic animals (each line represents one hybridoma). The positive control corresponds to a lysate from human Jurkat cells. The ratio of Bcl-2/GAPDH for each hybridoma is depicted under the respective lines. (C) Concentration of rat IgG in tissue culture supernatants at day 3 of culture (cells between 3.1 and 6 3 105 ml–1) measured by ELISA. Each point represents the values of one hybridoma supernatant and the horizontal bar the mean of each group of values *P < 0.05 hybridoma Bcl-2- (n = 4) versus hybridoma Bcl-2+
    Mouse Anti Human Bcl2 Mab, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-human bcl2 mab/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    mouse anti-human bcl2 mab - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    IVL DCM induces the apoptosis of A549 cells. A549 cells were treated with the indicated concentrations of IVL DCM for 48 h. ( A ) P53, BCL2, BAX, Caspase 3, c-Caspase 3, PARP, c-PARP protein levels as detected by immunoblotting of A549 cell lysates. β-actin was immunoblotted as a loading control ( B ). Quantification of the bands in ( A ). Bar graphs of band intensity of target proteins normalized to the intensity of the loading control β-actin expressed as fold change of the vehicle control and represented as the mean ± SEM of three independent experiments ( n = 3). The right panel of ( B ) shows the ratio of BAX/BCL2 ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

    Journal: Biology

    Article Title: Chemical Composition, Antioxidant Capacity, and Anticancerous Effects against Human Lung Cancer Cells of a Terpenoid-Rich Fraction of Inula viscosa

    doi: 10.3390/biology13090687

    Figure Lengend Snippet: IVL DCM induces the apoptosis of A549 cells. A549 cells were treated with the indicated concentrations of IVL DCM for 48 h. ( A ) P53, BCL2, BAX, Caspase 3, c-Caspase 3, PARP, c-PARP protein levels as detected by immunoblotting of A549 cell lysates. β-actin was immunoblotted as a loading control ( B ). Quantification of the bands in ( A ). Bar graphs of band intensity of target proteins normalized to the intensity of the loading control β-actin expressed as fold change of the vehicle control and represented as the mean ± SEM of three independent experiments ( n = 3). The right panel of ( B ) shows the ratio of BAX/BCL2 ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

    Article Snippet: Primary antibodies used were: anti-human poly-adenosine diphosphate (ADP) ribose polymerase (PARP) 46D11 rabbit mAb which can detect the full-length and cleaved forms of PARP (ref 9532 CST, dilution 1/1000), P53 rabbit mAb (ref 2527S CST, dilution 1/500), Ki67 rabbit polyclonal antibody (ref 28074-1-AP, Proteintech, Rosemont, IL, USA, dilution 1/1000), mouse anti-human B-cell lymphoma 2 (BCL2) (ref 15071S CST, dilution 1/1000), rabbit anti-Bcl-2 associated X protein (BAX) (D2E11 ref 5023 CST; dilution 1/1000), P38 MAPK polyclonal antibody (14064-1-AP, Proteintech, dilution 1/1000), phospho-p38 MAPK (Thr180/Tyr182) antibody(ref 9211 CST, dilution 1/1000), Caspase3 antibody (ref 9662 CST, 1/1000 dilution), cleaved Caspase3 (c-Caspase 3; Asp175) 5A1E rabbit mAb (ref 9664 CST, dilution 1/1000), β-actin 8H10D10 mouse mAb (ref 3760 CST, dilution 1/1000), P21 Waf1/Cip1 12D1 rabbit mAb (ref 2947 CST, 1/1000), P27 (CST, 1/1000), phospho-FAK (p-Fak Tyr 397) D20B1 rabbit mAb (ref 8556 CST, dilution 1/1000), FAK D2R2E rabbit mAb (ref 13009 CST, dilution 1/1000).

    Techniques: Western Blot, Control

    Fig. 7 | Single-cell transcriptomic analysis verifies lower CELSR2 and higher BCL2 in glucocorticoid-resistant primary ALL cells. a, Clustering of single cells (n = 2 patients) based on the top 1,000 most highly expressed genes. Both patients are independent of the discovery and validation cohorts; leukemia cells from one patient are sensitive (left) and from another are resistant to prednisolone (right). Clusters annotated to show CD19+ cells; red denotes control (untreated) and blue depicts cells after treatment with prednisolone 63 µM for 96 h. b, CELSR2 expression from clustered single-cell populations of sensitive and resistant patients either without treatment or after 96 h of prednisolone. c, BCL2 expression from clustered single-cell populations of sensitive and resistant patients. d, Bar plot depicting greater proportion of sensitive leukemia cells (n = 2,427 control cells; n = 924 treated cells) killed after treatment with prednisolone for 96 h compared with resistant patient (n = 686 control cells; n = 759 treated cells; two-proportion z-test P: ****P < 0.0001). e,f, Violin plots representing kernel density of gene expression (individual points represent single cells) of CELSR2 (e) or BCL2 (f) in CD19+ leukemia cell populations comparing prednisolone treated with untreated cells in sensitive (n = 2,427 control cells; n = 924 treated cells) or resistant patients (n = 686 control cells; n = 759 treated cells; **P < 0.01).

    Journal: Nature cancer

    Article Title: Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia.

    doi: 10.1038/s43018-020-0037-3

    Figure Lengend Snippet: Fig. 7 | Single-cell transcriptomic analysis verifies lower CELSR2 and higher BCL2 in glucocorticoid-resistant primary ALL cells. a, Clustering of single cells (n = 2 patients) based on the top 1,000 most highly expressed genes. Both patients are independent of the discovery and validation cohorts; leukemia cells from one patient are sensitive (left) and from another are resistant to prednisolone (right). Clusters annotated to show CD19+ cells; red denotes control (untreated) and blue depicts cells after treatment with prednisolone 63 µM for 96 h. b, CELSR2 expression from clustered single-cell populations of sensitive and resistant patients either without treatment or after 96 h of prednisolone. c, BCL2 expression from clustered single-cell populations of sensitive and resistant patients. d, Bar plot depicting greater proportion of sensitive leukemia cells (n = 2,427 control cells; n = 924 treated cells) killed after treatment with prednisolone for 96 h compared with resistant patient (n = 686 control cells; n = 759 treated cells; two-proportion z-test P: ****P < 0.0001). e,f, Violin plots representing kernel density of gene expression (individual points represent single cells) of CELSR2 (e) or BCL2 (f) in CD19+ leukemia cell populations comparing prednisolone treated with untreated cells in sensitive (n = 2,427 control cells; n = 924 treated cells) or resistant patients (n = 686 control cells; n = 759 treated cells; **P < 0.01).

    Article Snippet: *CHIP-seq paper* mouse anti-human BCL2 (Cell Signaling; 15071) - WB, IHC, IP, Flow mouse anti-human glucocorticoid receptor (BD Biosciences; 611227)- WB and IF validated mouse anti-human GAPDH (sc-47724)-WB and IHC validated mouse anti-human BIM monoclonal (Cell Signaling;2993)- WB and IHC, IP, Flow validated mouse anti-human GR (BD Biosciences; #611227)- WB and IHC validated mouse anti-human p-JNK (Santa Cruz Biotech; sc-6254)-WB and IHC validated rabbit anti-human cJun (Cell signaling; 9165) -WB, IP, Flow,CHIP,and IHC validated rabbit anti-human NFAT1 (Cell Signaling; 4389)- WB and IHC, IP validated rabbit anti-human phospho-cJun Ser63 (Santa Cruz Biotechnology; sc-822)-WB, IP, IFC and IHC validated rabbit anti-human LaminB1 (Cell Signaling; 12586)- WB validated mouse anti-human B-actin (Sigma-Aldrich; A5441) - Binding, ChIP, Control, Dot blot, EM, ICC, IF, IHC, IHC-Float, IP, In Vitro, and WB 3,551 citations on citeAB Anti-human CD19 PerCp-Cy5.5 (eBioscience; 45-0199-42) Flow validated Anti-mouse CD45-APC, (Tonbo; 20-0451-U100) Flow validated Eukaryotic cell lines Policy information about cell lines Cell line source(s) 697-DSMZ (ACC-42); NALM6- DSMZ (ACC 128); REH- DSMZ (ACC 22); SUP-B15 ATCC (CRL-1929); RS4;11 DSMZ(ACC 508); SEM DSMZ (ACC 546) Authentication Parental cell lines were authenticated by STR profiling Mycoplasma contamination Mycoplasma testing performed quarterly in lab on all cells all cells tested negative for mycoplasma Commonly misidentified lines (See ICLAC register) No commonly misidentified cell lines were used in this study Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals NOD-SCID gamma mice, Females 8-12 weeks, n=5 mice per treatment group, Total of 60 mice on study.

    Techniques: Biomarker Discovery, Control, Expressing, Gene Expression

    Fig. 6. Hybridoma characterization. (A) Binding constants (nanomolar) of mAbs generated with splenocytes from non-transgenic littermates (LM) and transgenic line 70818 animals (Bcl2) as determined by Biacore analysis (log scale nanomolar). (B) Western blot analysis of Bcl-2 expression in hybridomas from bcl-2 transgenic animals (each line represents one hybridoma). The positive control corresponds to a lysate from human Jurkat cells. The ratio of Bcl-2/GAPDH for each hybridoma is depicted under the respective lines. (C) Concentration of rat IgG in tissue culture supernatants at day 3 of culture (cells between 3.1 and 6 3 105 ml–1) measured by ELISA. Each point represents the values of one hybridoma supernatant and the horizontal bar the mean of each group of values *P < 0.05 hybridoma Bcl-2- (n = 4) versus hybridoma Bcl-2+

    Journal: International immunology

    Article Title: Effects of BCL-2 over-expression on B cells in transgenic rats and rat hybridomas.

    doi: 10.1093/intimm/dxr071

    Figure Lengend Snippet: Fig. 6. Hybridoma characterization. (A) Binding constants (nanomolar) of mAbs generated with splenocytes from non-transgenic littermates (LM) and transgenic line 70818 animals (Bcl2) as determined by Biacore analysis (log scale nanomolar). (B) Western blot analysis of Bcl-2 expression in hybridomas from bcl-2 transgenic animals (each line represents one hybridoma). The positive control corresponds to a lysate from human Jurkat cells. The ratio of Bcl-2/GAPDH for each hybridoma is depicted under the respective lines. (C) Concentration of rat IgG in tissue culture supernatants at day 3 of culture (cells between 3.1 and 6 3 105 ml–1) measured by ELISA. Each point represents the values of one hybridoma supernatant and the horizontal bar the mean of each group of values *P < 0.05 hybridoma Bcl-2- (n = 4) versus hybridoma Bcl-2+

    Article Snippet: Western blots were performed as previously described (26) using a mouse anti-human Bcl2 mAb (Abd Serotec) followed by incubation with HRP-conjugated goat anti-mouse IgG + IgM (H + L) antibodies (Jackson ImmunoResearch).

    Techniques: Binding Assay, Generated, Transgenic Assay, Western Blot, Expressing, Positive Control, Concentration Assay, Enzyme-linked Immunosorbent Assay